CLOFAZIMINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H22Cl2N4
Molecular Weight	473.396
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C4=CC=CC=C4N=C2C=C1NC5=CC=C(Cl)C=C5

InChI

InChIKey=WDQPAMHFFCXSNU-BGABXYSRSA-N

InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19500slr010_lamprene_lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68002991

Clofazimine (Lamprene®) is a fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine (Lamprene®) exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). It inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. It also exerts anti-inflammatory properties in controlling erythema nodosum leprosum reactions. However, its precise mechanisms of action are unknown.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 247 Target ID: CHEMBL2366041 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19500slr010_lamprene_lbl.pdf	Binding Agent 1059

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lepromatous leprosy 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19500slr010_lamprene_lbl.pdf	Curative		Approved 8360	LAMPRENE Approved Use Lamprene is indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. Lamprene has not been demonstrated to be effective in the treatment of other leprosy-associated inflammatory reactions. Launch Date 5.34988784E11

C_max

Value	Dose	Analyte	Population
469 pmol/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
604 pmol/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
861 pmol/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.5 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2656045/	300 mg 3 times / week multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.7 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2656045/	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2656045/	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1.4 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2656045/	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
18000 pmol × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29100 pmol × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
33900 pmol × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
10.6 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3559339/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		CLOFAZIMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3559339 Page: p.1986	unhealthy, 30-60 n = 6 Health Status: unhealthy Condition: Lepromatous leprosy Age Group: 30-60 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/3559339 Page: p.1986	Sources: https://pubmed.ncbi.nlm.nih.gov/3559339 Page: p.1986
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	Other AEs: Gastrointestinal obstruction, Gastrointestinal bleeding... Other AEs: Gastrointestinal obstruction (grade 3-5) Gastrointestinal bleeding (grade 3-5) Splenic infarction (grade 3-5) QT interval prolonged Torsade de pointes Discoloration urine Depression Suicidal ideation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1, p.3	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1, p.3	Other AEs: Skin discoloration... Other AEs: Skin discoloration (75-100) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1, p.3
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3	Other AEs: Ichthyosis, Dry skin... Other AEs: Ichthyosis Dry skin Pruritus Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3
200 mg single, oral Recommended Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.4	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.4	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.4

AEs

AE	Significance	Dose	Population
Depression		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Discoloration urine		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
QT interval prolonged		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Suicidal ideation		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Torsade de pointes		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Gastrointestinal bleeding	grade 3-5	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Gastrointestinal obstruction	grade 3-5	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Splenic infarction	grade 3-5	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1
Skin discoloration	75-100	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1, p.3	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.1, p.3
Dry skin		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3
Ichthyosis		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3
Pruritus		100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Lepromatous leprosy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf Page: p.3

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 768 inhibitor 1579		inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1437 BCRP 691 MRP1 106 BSEP 401

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26682943/	strong [IC50 1.8 uM]
BCRP 765	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26682943/	strong [IC50 3.2 uM]
MRP1 172	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26682943/	strong [IC50 6.8 uM]
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26094899/;https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf#page=8 Page: 4.0	yes [IC50 0.275 uM]	no (co-administration study) Comment: No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with clofazimine: dapsone or rifampicin Sources: https://pubmed.ncbi.nlm.nih.gov/26094899/;https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf#page=8 Page: 4.0
BSEP 402	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/19520776/ Page: 7.0	yes [IC50 2.3 uM]
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26094899/;https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf#page=8 Page: 4.0	yes [IC50 4.54 uM]	no (co-administration study) Comment: No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with clofazimine: dapsone or rifampicin Sources: https://pubmed.ncbi.nlm.nih.gov/26094899/;https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf#page=8 Page: 4.0
CYP3A4 1909	inducer 1542 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068461/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3749	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3749
MolPort	MolPort-042-621-745	https://www.molport.com/shop/molecule-link/MolPort-042-621-745
ZINC	ZINC000253916263	http://zinc15.docking.org/substances/ZINC000253916263

PubMed

Title	Date	PubMed
Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?	1992 Dec	1303690
In-vivo activity of streptomycin and clofazimine against established infections of Mycobacterium avium complex in beige mice.	1992 Dec	1289358
[Immuno-allergic accidents with rifamipcin].	2001-2002	12136739
Clinical management of pyoderma gangrenosum.	2002	11978136
Treatment of Hansen's disease.	2002 Apr 1	11996412
Biochemical and hematological side effects of clofazimine in leprosy patients.	2002 Aug	12220960
Pyoderma gangrenosum: a report of 21 cases.	2002 Feb	11982638
Treatment with drugs active against Mycobacterium avium subspecies paratuberculosis can heal Crohn's disease: more evidence for a neglected public health tragedy.	2002 Jan	11926580
Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure?	2002 Jan	11926571
Advances in the diagnosis and treatment of leprosy.	2002 Jul 22	14585155
Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study.	2002 Jul-Sep	12708702
Successful treatment of postoperative pyoderma gangrenosum with cyclosporin.	2002 Mar	12046819
[Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease].	2002 Oct	12297950
Bullous reaction in leprosy: a rare phenomenon.	2002 Sep	12483969
[Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].	2002 Sep-Oct	12621663
[Histoid leprosy with erythema nodosum leprosum].	2003	15040700
[Hansen's disease in the laboratory].	2003	14650417
Probing cell chemistry with time-of-flight secondary ion mass spectrometry: development and exploitation of instrumentation for studies of frozen-hydrated biological material.	2003	14515313
[A case of lepromatous type Hansen's disease].	2003 Aug	14598637
Dapsone induced cholangitis as a part of dapsone syndrome: a case report.	2003 Aug 11	12911838
Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.	2003 Dec	14763888
Chronic recurrent ENL, steroid dependent: long-term treatment with high dose clofazimine.	2003 Dec	14750585
Leprosy in a Mexican immigrant.	2003 Jul	12886712
Efficacy of clofazimine-modified cyclodextrin against Mycobacterium avium complex in human macrophages.	2003 Jul 9	12818815
Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.	2003 Jun	12862255
Disseminated Mycobacterium chelonae cutaneous infection: recalcitrant to combined antibiotic therapy.	2003 Jun	12810998
A retrospective study regarding the treatment of lupoid onychodystrophy in 30 dogs and literature review.	2003 Mar-Apr	12617542
[Leprosy in Brazil].	2003 May-Jun	12908039
Invasive Mycobacterium marinum infections.	2003 Nov	14725262
Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.	2003 Sep	14608816
Determination of clofazimine in leprosy patients by high-performance liquid chromatography.	2003 Sep	14516492
Along these lines..	2003 Sep	12956684
Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses.	2003 Sep-Oct	14973643
Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients.	2004	15186195
Human case of lobomycosis.	2004 Apr	15200867
Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol.	2004 Apr 15	15050732
Morbihan's disease: treatment with CO2 laser blepharoplasty.	2004 Feb	15160865
A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents.	2004 Feb	15139456
[Guideline for the treatment of leprosy by new quinolones].	2004 Feb	15035068
Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.	2004 Feb	14993633
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method.	2004 Jan	14645324
Cheilitis granulomatosa of Melkersson-Rosenthal syndrome: treatment with intralesional corticosteroid injections.	2004 Jan-Feb	14980194
Intra-abdominal, crystal-storing histiocytosis due to clofazimine in a patient with lepromatous leprosy and concurrent carcinoma of the colon.	2004 Jun	15282969
Shiny red-brown papules in a 21-year-old man. Histoid leprosy.	2004 Jun	15210473
Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases.	2004 Jun	15117926
Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years.	2004 Mar	15217321
Erythema dyschromicum perstans: response to dapsone therapy.	2004 Mar	15009398
Anti-staphylococcal activity and mode of action of clofazimine.	2004 Mar	14762055
Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.	2004 May	15137531
10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.	2004 Sep 9	15315844

Patents

Sample Use Guides

In Vivo Use Guide

Lamprene® should be given at a dosage of 100 mg daily in combination with one or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of Lamprene® daily. It should be taken with meals.

Route of Administration: Oral

In Vitro Use Guide

The following in vitro data are available, but their clinical significance is unknown. Lamprene® has been shown in vitro to inhibit M. avium and M. bovis at concentrations of approximately 0.1-1.0 ug/mL. The MIC for M. avium-intracellulare isolated from patients with acquired immunodeficiency syndrome (AIDS) ranged from 1.0 to 5.0 ug/mL.

Name

Type

Language

CLOFAZIMINE

Official Name

English

G-30320

Code

English

CLOFAZIMINE [WHO-IP]

Common Name

English

CLOFAZIMINE [MI]

Common Name

English

CLOFAZIMINE [USP IMPURITY]

Common Name

English

CLOFAZIMINE [USP MONOGRAPH]

Common Name

English

CLOFAZIMINE [EP MONOGRAPH]

Common Name

English

Clofazimine [WHO-DD]

Common Name

English

2-PHENAZINAMINE, N,5-BIS(4-CHLOROPHENYL)-3,5-DIHYDRO-3-((1-METHYLETHYL)IMINO)-

Systematic Name

English

CLOFAZIMINUM [WHO-IP LATIN]

Common Name

English

clofazimine [INN]

Common Name

English

CHLOFAZIMINE

Common Name

English

CLOFAZIMINE [ORANGE BOOK]

Common Name

English

3-(P-CHLOROANILINO)-10-(P-CHLOROPHENYL)-2,10-DIHYDRO-2-(ISOPROPYLIMINO)PHENAZINE

Common Name

English

CLOFAZIMINE [USAN]

Common Name

English

G 30320

Code

English

COLFAZIMINE [VANDF]

Common Name

English

CLOFAZIMINE [VANDF]

Common Name

English

CLOFAZIMINE [USP-RS]

Common Name

English

CLOFAZIMINE [JAN]

Common Name

English

NSC-141046

Code

English

CLOFAZIMINE [MART.]

Common Name

English

LAMPRENE

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

770820